Ulla Olsson‐Strömberg

3.6k total citations
53 papers, 1.5k citations indexed

About

Ulla Olsson‐Strömberg is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Ulla Olsson‐Strömberg has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 34 papers in Genetics and 15 papers in Oncology. Recurrent topics in Ulla Olsson‐Strömberg's work include Chronic Myeloid Leukemia Treatments (40 papers), Chronic Lymphocytic Leukemia Research (34 papers) and Eosinophilic Disorders and Syndromes (10 papers). Ulla Olsson‐Strömberg is often cited by papers focused on Chronic Myeloid Leukemia Treatments (40 papers), Chronic Lymphocytic Leukemia Research (34 papers) and Eosinophilic Disorders and Syndromes (10 papers). Ulla Olsson‐Strömberg collaborates with scholars based in Sweden, Finland and Norway. Ulla Olsson‐Strömberg's co-authors include Satu Mustjoki, Bengt Simonsson, Angelica Loskog, Johan Richter, Leif Stenke, Lisa Christiansson, Martin Höglund, Stina Söderlund, Henrik Hjorth‐Hansen and Berit Markevärn and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ulla Olsson‐Strömberg

51 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulla Olsson‐Strömberg Sweden	21	865	608	439	366	355	53	1.5k
Anita Badbaran Germany	23	972 1.1×	589 1.0×	419 1.0×	570 1.6×	215 0.6×	72	1.5k
Tinisha McDonald United States	12	868 1.0×	372 0.6×	543 1.2×	753 2.1×	361 1.0×	30	1.7k
Cecily L. Wait United States	8	563 0.7×	321 0.5×	313 0.7×	347 0.9×	244 0.7×	9	1.5k
George F. Barker United States	6	924 1.1×	470 0.8×	260 0.6×	713 1.9×	166 0.5×	7	1.6k
Virginia Kelly United States	16	453 0.5×	624 1.0×	394 0.9×	322 0.9×	232 0.7×	34	1.2k
Thomas G.P. Bumm United States	13	771 0.9×	819 1.3×	336 0.8×	468 1.3×	132 0.4×	24	1.3k
N Philippe France	13	1.1k 1.2×	626 1.0×	213 0.5×	545 1.5×	106 0.3×	33	1.5k
Bartlomiej Przychodzen United States	20	1.1k 1.2×	557 0.9×	144 0.3×	834 2.3×	304 0.9×	105	1.7k
Jason A. Dubovsky United States	20	611 0.7×	703 1.2×	316 0.7×	493 1.3×	577 1.6×	45	1.6k
Luisa Anelli Italy	23	693 0.8×	436 0.7×	149 0.3×	563 1.5×	83 0.2×	87	1.3k

Countries citing papers authored by Ulla Olsson‐Strömberg

Since Specialization

Citations

This map shows the geographic impact of Ulla Olsson‐Strömberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulla Olsson‐Strömberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulla Olsson‐Strömberg more than expected).

Fields of papers citing papers by Ulla Olsson‐Strömberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulla Olsson‐Strömberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulla Olsson‐Strömberg. The network helps show where Ulla Olsson‐Strömberg may publish in the future.

Co-authorship network of co-authors of Ulla Olsson‐Strömberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ulla Olsson‐Strömberg. A scholar is included among the top collaborators of Ulla Olsson‐Strömberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulla Olsson‐Strömberg. Ulla Olsson‐Strömberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wiberg, Anna, Payam Emami Khoonsari, Henrik Carlsson, et al.. (2023). Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients. Lipids in Health and Disease. 22(1). 97–97. 5 indexed citations

Huuhtanen, Jani, Shady Adnan Awad, Olli Dufva, et al.. (2023). Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 38(1). 109–125. 17 indexed citations

Dahlén, Torsten, Gustaf Edgren, Per Ljungman, et al.. (2022). Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. American Journal of Hematology. 97(4). 421–430. 8 indexed citations

Richter, Johan, Anna Lübking, Stina Söderlund, et al.. (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia. 35(8). 2416–2418. 16 indexed citations

Söderlund, Stina, Inger Persson, Mette Ilander, et al.. (2020). Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy. Leukemia Research. 90. 106310–106310. 5 indexed citations

Lübking, Anna, Arta Dreimane, Fredrik Sandin, et al.. (2019). Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplantation. 54(11). 1764–1774. 25 indexed citations

Wiberg, Anna, Ulla Olsson‐Strömberg, Stephanie Herman, Kim Kultima, & Joachim Burman. (2019). Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(1). 50–57. 12 indexed citations

Rajala, Hanna, Perttu Koskenvesa, Tim H. Brümmendorf, et al.. (2017). Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143(8). 1543–1554. 19 indexed citations

Söderlund, Stina, Lisa Christiansson, Inger Persson, et al.. (2016). Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leukemia Research. 50. 95–103. 20 indexed citations

10.

Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30(9). 1853–1860. 49 indexed citations

11.

Awad, Shady Adnan, Hanna Rajala, Ahmed Al‐Samadi, et al.. (2016). Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. Journal of Cancer Research and Clinical Oncology. 142(5). 1041–1050. 15 indexed citations

12.

Christiansson, Lisa, Stina Söderlund, Sara M. Mangsbo, et al.. (2015). The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. Molecular Cancer Therapeutics. 14(5). 1181–1191. 57 indexed citations

13.

Skoglund, Karin, Johan Richter, Ulla Olsson‐Strömberg, et al.. (2015). In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. Therapeutic Drug Monitoring. 38(2). 230–238. 10 indexed citations

14.

Cavelier, Lucia, Adam Ameur, Ida Höijer, et al.. (2015). Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. BMC Cancer. 15(1). 45–45. 35 indexed citations

15.

Karlsson, Hannah, Emma Svensson, Malin Jarvius, et al.. (2015). Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors. PLoS ONE. 10(12). e0144787–e0144787. 89 indexed citations

16.

Christiansson, Lisa, Ingrid Thörn, Sara M. Mangsbo, et al.. (2011). Both CD4⁺ FoxP3⁺ and CD4⁺ FoxP3⁻ T cells from patients with B‐cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 133(3). 296–306. 41 indexed citations

17.

Olsson‐Strömberg, Ulla, Tuija Lundán, Martin Höglund, et al.. (2010). Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib. European Journal Of Haematology. 85(5). 399–404. 3 indexed citations

18.

Christiansson, Lisa, et al.. (2010). T regulatory cells control T‐cell proliferation partly by the release of soluble CD25 in patients with B‐cell malignancies. Immunology. 131(3). 371–376. 64 indexed citations

19.

Olsson‐Strömberg, Ulla, Hanna Göransson, Anders Isaksson, et al.. (2007). Gene expression analysis identifies a genetic signature potentially associated with response to α-IFN in chronic phase CML patients. Leukemia Research. 31(7). 931–938. 4 indexed citations

20.

Olsson‐Strömberg, Ulla, Anna Åleskog, Martin Höglund, et al.. (2006). Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-Cancer Drugs. 17(6). 631–639. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact